N-(4-acetylphenyl)-2-methyl-propanamide | 128184-26-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-(4-acetylphenyl)-2-methyl-propanamide
• 英文别名: N-(4-acetylphenyl)isobutyramide；4-isobutyrylaminoacetophenone；N-(4-acetylphenyl)-2-methylpropanamide
• CAS: 128184-26-9
• 化学式: C₁₂H₁₅NO₂
• mdl: MFCD00448088
• 分子量: 205.257
• InChiKey: PYYFWHKFMKTHDQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(4-acetylphenyl)-2-methyl-propanamide 在 三氯化铝 、 溴 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 4-isobutyrylaminophenacyl bromide
  参考文献：
  名称：

  Synthesis and Biological Activity of Strongly Fluorescent Tricyclic Analogues of Acyclovir and Ganciclovir

  摘要：

  In search of strongly fluorescent tricyclic analogues of acyclovir (ACV, 1) and ganciclovir (GCV, 2), derivatives of the 3,9-dihydro-9-oxo-5H-imidazo[1,2-alpha]purine system, several 6-[4-(acyloxy)phenyl], 6- [4-(acylamino)phenyl], and 6- [4-(phenoxycarbonyloxy)phenyl]-substituted TACV and TGCV analogues were synthesized and evaluated for their activity against herpes simplex virus types 1 and 2 in cell culture. All TACV and TGCV analogues showed strong fluorescence (quantum yield of 30-65% vs 2-aminopurine 100%). The 6-[4-(phenoxycarbonyloxy)phenyl]-substituted compounds 11 and 19 displayed the best combination of the fluorescence and antiviral potency.

  DOI：

  10.1021/jm020827z
• 作为产物：
  描述：

  异丁酰胺 、 对氯苯乙酮 在 三仲丁基硼烷 、 (DiMeIHeptCl)Pd(cinammyl)Cl 、 caesium carbonate 作用下， 以 甲苯 为溶剂， 反应 24.0h， 以83%的产率得到N-(4-acetylphenyl)-2-methyl-propanamide
  参考文献：
  名称：

  使用由三烷基硼烷或 BCF 促进的 (DiMeIHeptCl)Pd 将伯酰胺与芳基和杂芳基伙伴交叉偶联。

  摘要：

  硼衍生的路易斯酸已被证明可以使用 Pd-NHC 催化剂有效地促进酰胺亲核试剂与各种氧化加成伙伴的偶联。通过结合 NMR 光谱和有和没有氧和自由基清除剂的对照研究，我们建议在基本反应条件下形成硼酰亚胺，这有助于氮与 Pd(II) 的配位，这是限速的，并直接提供中间体用于还原消除。

  DOI：

  10.1021/jacs.7b09488

文献信息

• A Light-Activated Antibody Catalyst
  作者：Matthew J. Taylor、Timothy Z. Hoffman、Jari T. Yli-Kauhaluoma、Richard A. Lerner、Kim D. Janda

  DOI：10.1021/ja982711r

  日期：1998.12.1

  per antibody) occurred. The singular product obtained in the antibody-catalyzed reaction was not observed in the uncatalyzed reaction unless the pH was lowered below 4. Studies suggested that the interplay of conformational control and chemical catalysis were responsible for the high specificity. A change in protonation state of the antibody was correlated with the inclusion of a new reaction pathway

  研究了用于多步 Norrish II 型光化学反应的催化抗体。α-酮酰胺底物 1b 吸收光能产生高能双自由基中间体，然后由抗体微环境引导形成四氢吡嗪 13，在 280 nm 照射下 kcat 为 1.4 × 10-3 min-1，对映体过量78%。用放射性标记底物进行的抗体催化反应表明几乎没有发生自我失活（每个抗体四次转换后 6.8 mol% 的共价修饰）。在未催化反应中观察不到在抗体催化反应中获得的单一产物，除非 pH 值低于 4。研究表明，构象控制和化学催化的相互作用是造成高特异性的原因。
• [EN] MDM2 DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION DE MDM2 ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2021188948A1

  公开（公告）日：2021-09-23

  The present invention relates to compounds and methods useful for the modulation of mouse double minute 2 homolog ("MDM2") protein via ubiquitination and/or degradation by compounds according to the present invention.

  本发明涉及化合物和方法，通过本发明的化合物对小鼠双分子2同源蛋白（"MDM2"）蛋白进行泛素化和/或降解的调节。
• Nickel-Catalyzed Dehydrogenative Cross-Coupling: Direct Transformation of Aldehydes into Esters and Amides
  作者：Aaron M. Whittaker、Vy M. Dong

  DOI：10.1002/anie.201410322

  日期：2015.1.19

  nickel‐catalyzed cross‐coupling, a method to directly transform both aromatic and aliphatic aldehydes into either esters or amides has been developed. The success of this oxidative coupling depends on the appropriate choice of catalyst and organic oxidant, including the use of either α,α,α‐trifluoroacetophenone or excess aldehyde. Mechanistic data that supports a catalytic cycle involving oxidative addition into

  通过探索镍催化交叉偶联的新模式，开发了一种将芳香族和脂肪族醛直接转化为酯或酰胺的方法。这种氧化偶联的成功取决于催化剂和有机氧化剂的适当选择，包括使用α,α,α-三氟苯乙酮或过量的醛。还提供了支持涉及醛 C - H 键氧化加成的催化循环的机理数据。
• Structure-based modification of 3-/4-aminoacetophenones giving a profound change of activity on tyrosinase: From potent activators to highly efficient inhibitors
  作者：Ao You、Jie Zhou、Senchuan Song、Guoxun Zhu、Huacan Song、Wei Yi

  DOI：10.1016/j.ejmech.2015.02.013

  日期：2015.3

  In this study, we developed 3-/4-aminoacetophenones and their structure-based 3-/4-aminophenylethylidenethiosemicarbazide derivatives, respectively, as novel tyrosinase activators and inhibitors. Notably, all the obtained thiosemicarbazones displayed more potent tyrosinase inhibitory activities than kojic acid. Especially, compound 7k was found to be the most active tyrosinase inhibitor with IC50 value of 0.291 mu M. The structure-activity relationships (SARs) analysis showed that: (1) the amine group was absolutely necessarily for determining the tyrosinase activation activity; (2) the introduction of thiosemicarbazide group played a very vital role in transforming tyrosinase activators into tyrosinase inhibitors; (3) the phenylethylenethiosemicarbazide moiety was crucial for determining the tyrosinase inhibitory activity; (4) the type of acyl group had no obvious effect on the inhibitory activity; (5) the position of amide substituent on the phenyl ring influenced the tyrosinase inhibitory potency. Moreover, the inhibition mechanism and inhibition kinetics study revealed that compound 7k was reversible and non-competitive inhibitor, and compound 8h was reversible and competitive-uncompetitive mixed-II type inhibitor. (C) 2015 Elsevier Masson SAS. All rights reserved.
• SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF
  申请人：ZHAO Robert Yongxin

  公开号：US20210052747A1

  公开（公告）日：2021-02-25

  The present invention relates to novel linkers containing a 2,3-disubstituted succinic group, or 2-monosubstituted, or 2,3-disubstituted fumaric or maleic (trans (E)-or cis (Z)-butenedioic), or acetylenedicarboxyl group for conjugation of a cytotoxic agent, and/or one or more different functional molecules per linker to a cell-binding molecule, through bridge linking pairs of thiols on the cell-binding molecule specifically. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.